COBRA Lab at the Douglas Research Centre Supercharges TRIDENT with Rodent Automated BOLD Improvement of EPI Sequences (RABIES)
This open-source pipeline, newly showcased in Nature Communications, scrubs, aligns, and quality-checks any mouse or rat fMRI scan, stripping out scanner, anesthesia, and processing noise so that noisy images become reproducible brain-network maps. This gold-standard workflow, now the backbone of TRIDENT’s Data Management and Sharing Core, is tightening the link between rodent models and human-relevant neurotherapeutic discovery while championing open, transparent science.

Learn more about the TRIDENT Data Management and Sharing Core HERE.

EDDU Neuro at McGill University Propels TRIDENT with CelltypeR
Published in iScience, CelltypeR pairs a multi-marker, flow-cytometry panel with an R analytics pipeline to convert iPSC-derived midbrain organoids into crisp, cell-resolved maps, pinpointing astrocytes, radial glia, and vulnerable nigral-like dopamine neurons. TRIDENT’s iPSC & Organoid Core leverages this open workflow to ensure rigorous quality control, speeding-up human-relevant neurotherapeutic testing. 

Learn more about the TRIDENT iPSC & Organoid Core HERE.

TRIDENT Mouse Core Links Imaging, Touchscreen Cognition, and Circuit Control for Next-Generation Drug Testing
A recent Journal of Neurochemistry study pairs high-resolution MRI with Bussey-Saksida touchscreen reversal-learning, flagging subtle brain atrophy and cognitive slips as α-synuclein spreads long before motor symptoms appear. A follow-up in Communications Biology shows that male and female mice follow distinct MRI and survival trajectories, confirming that sex-balanced designs are essential for reliable efficacy calls. Capping the workflow, a new Nature Protocols guide bolts optogenetics, fiber photometry, and microendoscopic calcium imaging onto the same touchscreen tasks, letting researchers observe and steer the very circuits they aim to rescue. Together these advances hand TRIDENT a seamless translational pipeline that maps pathology, measures touchscreen cognition, and manipulates neural networks in both sexes well before overt disease, sharpening every preclinical therapeutic screen.

Learn more about the TRIDENT Mouse Core HERE.

Western Marmoset Core at TRIDENT Delivers an Awake Ultra-high-field fMRI Workflow for Drug Testing
Published in STAR Protocols,  this protocol details head-post surgery, gentle acclimation, and scanning that capture crisp functional maps without anesthesia noise in marmosets. The method lets researchers watch disease circuits unfold in the same animal before and after treatment, giving TRIDENT a primate-relevant read-out of pathology and efficacy. The protocol now anchors TRIDENT’s preclinical imaging pipeline, and the McGill Marmoset Core plans to adapt it for upcoming drug studies. 

Learn more about the TRIDENT Marmoset Core HERE.

Open Science, Practices and Policies Core at TRIDENT Proposes Flexible Incentives for Collaborative Drug Discovery
Published in Frontiers in Medicine, this policy mini-review argues that patent-centric rules sideline many researchers, patient groups, and nonprofits whose data drive breakthroughs. It lists practical levers such as adjustable data exclusivity periods, milestone vouchers, and shared IP credits that let contributors share knowledge early while still earning fair returns. The blueprint equips TRIDENT with a policy playbook that marries open science and sustainable rewards, helping discoveries move smoothly from bench to bedside. 

Learn more about the TRIDENT Open Science, Practices and Partnerships Core HERE.

Sex-Based Analysis Plus Core at TRIDENT Lays the Roadmap for Sex-Balanced drug discovery
Published in The BMJ, this work highlights that women’s conditions still attract only a fraction of research funds, clinical trials under-enroll women, and preclinical studies rarely analyze results by sex. The article calls for ring-fenced funding, compulsory sex-weighted analysis from cells to clinics, and training for every researcher. TRIDENT is turning these recommendations into a platform-wide rule, so every assay, organoid, and animal study will report male and female outcomes side by side, closing a data gap that has long slowed therapeutic progress for half the world. 

Learn more about the TRIDENT SBA+ Core HERE.

HQP Spotlight:
Sam Laxer, Imaging Core

READ MORE

HQP Spotlight: Farhad Ziarani,
Data Management & Sharing Core

READ MORE

HQP Spotlight: Paula Lepine,
iPSC & Organoid Core

READ MORE

HQP Spotlight:
Dr. Laura Gravelsins, SBA+ Core

READ MORE

Of Mice and Medicine: Navigating the Leap from Preclinical Research to Clinical Practice — Blog Post by Dr. Annoosha Attaran et al.

​​​​​​

READ MORE

Revolutionizing Neurodegenerative Drug Discovery: Accelerating Drug Discovery Through Public-Private Partnerships —​​​​​​​ Blog Post by Dr. Oren Princz-Lebel

READ MORE

Navigating the Future of Neurotherapeutics:
Insights from the ITN-TRIDENT Event — Blog Post by Latiyah Timothy

READ MORE